PHOENIX, Arizona, October 24, 2018 /PRNewswire/ --

Patent

Bioscience Pharma Partners ("BPP") announced today that it has been granted a patent by the U.S. Patent and Trademark Office (USPTO) for the use of its 5-Lipoxygenase activating protein (FLAP) inhibitor, BPP-1001, as an oral therapeutic for neuroinflammation and neuroinflammation-mediated damage resulting from traumatic or acquired insult or injury in the CNS.

Once considered a bystander phenomenon, neuroinflammation is now broadly accepted as elemental in the progression of neurodegenerative disease. The BPP therapeutic, via both its inhibition of the biosynthesis of all four leukotrienes in the central nervous system and its associated reduction in neuronal damage, neuronal death, astrocyte cell death and cognitive deficits, targets all neuroinflammation-mediated disorders and diseases, including post-concussion syndrome (PCS), multiple sclerosis, Parkinson's disease and Alzheimer's disease.

About Bioscience Pharma Partners

Bioscience Pharma Partners, is a clinical-stage biotechnology company developing BPP-1001 via the FDA's accelerated 505(b)2 regulatory pathway. A pivotal study of BPP-1001, in a PCS population whose symptoms of neuroinflammation have remained unresolved, is scheduled for H1 2019, following which BPP will actively seek breakthrough therapy status for the compound.

Senior Appointment

Dr Jason Kralic has been appointed as Director of Business Development by BPP. Dr Kralic was previously Head of Neurosciences Business Development at GlaxoSmithKline, where he was responsible for therapy-area BD strategy, due diligence and licensing. He has served in similar roles at Opexa Therapeutics, UCB Pharma and Schwarz Biosciences. Doug Stephan, President of BPP said "Jason brings a wealth of scientific perspective and business development expertise and knowledge to our Company and we are delighted to have him join our team."

PharmaVentures Ltd.

BPP has engaged PharmaVentures Ltd., ("PV"), the leading worldwide experts in deals and alliances for the Pharmaceutical Industry. PV's role is to source, on behalf of BPP, a global partner/licensee to develop and commercialise BPP-1001 for treatment of neuroinflammation-mediated disorders.

BioEurope 2018

BPP and PV are actively participating in the BioEurope 2018 conference in Copenhagen, Denmark from November 5^th-7^th. The companies are pleased to engage in further dialogue with potential global licensing partners regarding the significant anti-neuroinflammatory benefits of BPP-1001.

For Information Contact:

Bioscience Pharma Partners, LLC
Jason Kralic
Director of Business Development
+1-919-491-4995
jason@biosciencepharma.com 
www.biosciencepharma.com 

PharmaVentures Ltd.
Gavin Clark
Senior Advisor
+44-7867-504-793
gavin@pharmaventures.com 
www.pharmaventures.com

SOURCE Pharma Ventures Ltd